Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072266 · ClinicalTrials.gov registry record · Phase 1
A Dose-escalation Study in Subjects With Advanced Malignancies
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT01072266 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 45 participants.
The verdict
NCT01072266, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is an open label, dose escalation study using a 3 + 3 design to determine if INCB028060 (study drug) is safe, well-tolerated and effective in patients with advanced malignancies. Patients will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group is enrolled and may begin to receive study drug. Doses will be escalated unless a dose-limiting toxicity (DLT) is observed in one of three subjects.
Interventions
- DRUG INCB028060
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01072266
The ClinicalTrials.gov registry entry for NCT01072266 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB028060 is the first listed.
NCT01072266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01072266 about?
NCT01072266 is a clinical study titled "A Dose-escalation Study in Subjects With Advanced Malignancies". This is an open label, dose escalation study using a 3 + 3 design to determine if INCB028060 (study drug) is safe, well-tolerated and effective in patients with advanced malignancies. Patients will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next gro...
What is the current status of trial NCT01072266?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2010-01. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01072266?
The interventions under investigation include: INCB028060 (DRUG).
Who is sponsoring clinical trial NCT01072266?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.